MedPath

‘Saving the brain’

Not yet recruiting
Conditions
Head-neck cancer
Registration Number
NL-OMON24435
Lead Sponsor
Medical Imaging Center, UMCG
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
40
Inclusion Criteria

?adults (18-70 years),
?referred for treatment of tumours located in nasopharynx, oropharynx and sinonasal cavity with radiotherapy (photons or protons), with or without systemic treatment, with a close proximity of 1.5 cm of the clinical target volume (CTV elective dose) to the brain or brainstem.

Exclusion Criteria

?age <18 or > 70 years old at baseline;
?brain neurological disease other than consequences of head and neck cancer and its treatment (like a stroke);
?history of psychiatric disease;
?history of chemotherapy or radiotherapy for other tumours;
?chronic treatment with verapamil at baseline;
?pregnancy;
?contradictions for performing MRI, such as non-MRI compatible heart pacemaker, metallic foreign body in the eye, aneurysm clip in the brain or claustrophobic patient;
?contrast allergies.

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The occurrence, location and appearance of brain microvascular and white matter radiotherapy-induced changes on sequentially obtained MRI & PET images performed in several time points in comparison with the baseline MRI and PET images and conventional MRI images.
Secondary Outcome Measures
NameTimeMethod
Is there an association between the early brain damage demonstrated with MRI and PET imaging with the subsequent occurrence later brain damage on MRI and PET and cognitive and neurobehavioral changes in patients treated for head and neck tumours? <br>Have patients that received proton therapy less brain damage than patients with photon therapy?
© Copyright 2025. All Rights Reserved by MedPath